History 2021 2021 12th JAN Chronicle Title We are a team of entrepreneurial scientists...
#药闻简讯#2024年10月29日,$葛兰素史克(GSK)$和Chimagen Biosciences(恩沐生物)宣布了一项协议,葛兰素史克将以3亿美元首付款从Chimagen收购CMG1A46,这是一款临床阶段的CD19和CD20双重靶向T细胞接合剂(TCE)。 葛兰素史克计划开发和商业化CMG1A46,重点关注B细胞驱动的自身免疫性疾病,如系统性红斑狼疮(SLE)和狼疮性肾...
签下8.5亿美元协议 拓展红斑狼疮管线 日前,葛兰素史克(GSK)官方发布消息,其与中国创新药企业恩沐生物(Chimagen Biosciences)达成关于三特异性抗体CMG1A46的收购协议。据此,GSK将向恩沐生物支付3亿美元的预付款,从而获得CMG1A46的全部全球权利(除大中华区外)。此外,恩沐生物还将有资格获得总额为5.5亿美元的CMG1A46...
Chimagen Biosciences is a clinical-stage biotechnology company focused on the discovery and development of novel multi-specific T cell-engagers and NK cell-engagers generated by proprietary antibody engineering platforms. Its mission is to advance breakthrough therapies that impr...